Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

PAVmed (PAVM) Preferred Shares Issued (2017 - 2024)

PAVmed has reported Preferred Shares Issued over the past 2 years, most recently at $11.6 million for Q2 2024.

For Q2 2024, Preferred Shares Issued changed N/A year-over-year to $11.6 million; the TTM value through Dec 2024 reached $34.8 million, up 86.83%, while the annual FY2024 figure was $29.8 million, 59.99% up from the prior year.
Preferred Shares Issued for Q2 2024 was $11.6 million at PAVmed, down from $18.2 million in the prior quarter.
Over five years, Preferred Shares Issued peaked at $18.2 million in Q1 2024 and troughed at $5.0 million in Q4 2023.